Understanding gastric cardia vs non-cardia cancer using multiomics

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational case-control study that collects clinical data and multiple biological samples (saliva, serum, tissue, and feces) from participants with gastric cancer and matched controls. The goal is to identify molecular differences between cardia and non-cardia tumors using combined omics analyses. Participants are adults aged 18-75 who have a confirmed pathological diagnosis and have not had recent gastric surgery or treatments that could confound results. Samples and data will be analyzed to see if multiomics signatures can support early screening distinctions between the two cancer subtypes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Study population signing informed consent form
* Age: 18-75 years old
* The study population must underwent endoscopic examination and was confirmed by pathological diagnosis as gastric cancer: including high-level intraepithelial neoplasia, early gastric cancer, and advanced gastric cancer.

Exclusion Criteria:

* Those who have undergone gastrointestinal surgery within the past 1 year; Patients who have undergone neoadjuvant chemotherapy and have developed tumors in the residual stomach after previous partial gastrectomy.
* Those who have used proton pump inhibitors, antibiotics, probiotics, and prebiotics daily within the past month, and those who have recently received hormone therapy.
* People with infectious diseases and other digestive system diseases that interfere with the experimental results, such as inflammatory bowel disease, irritable bowel syndrome, etc.

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Miaomiao Ma, Bachelor
• Email: mmiao6098@163.com
• Phone: (86)17657686098

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Perioperative biomarker monitoring to spot complications after colorectal and gastric cancer surgery

  This randomized trial tests whether checking inflammatory and metabolic biomarkers during the perioperative period helps detect postoperative problems early in adults having colorectal or gastric cancer surgery.

  Recruiting Bucharest Emergency Hospital · Bucharest, Bucharest · NCT07881133

• Lenvatinib with nivolumab and chemotherapy for metastatic gastric cancer with malignant ascites

  This trial tests whether adding lenvatinib to nivolumab plus chemotherapy helps people with metastatic gastric or gastroesophageal junction adenocarcinoma who have peritoneal metastases and significant malignant ascites.

  Recruiting Phase 1/2 Asan Medical Center · Seoul · NCT07149090

• 18F-FAPI PET/CT and laparoscopy for staging advanced stomach cancer

  This trial tests whether an 18F-FAPI PET/CT scan, used with laparoscopy, can better find spread of advanced stomach cancer and help doctors avoid unnecessary surgery.

  Recruiting Phase 2/3 Leiden University Medical Center · Almelo and 9 other locations · NCT07018661

• Evaluating outcomes in gastric cancer patients before and after a Tumor Board implementation

  This study is trying to see if having a team of experts work together improves the surgery and treatment results for people with gastric cancer.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, IT · NCT06923449

• Neoadjuvant zolbetuximab with docetaxel, oxaliplatin and S-1 for locally advanced stomach cancer

  This study will test whether adding zolbetuximab to docetaxel, oxaliplatin, and S-1 before surgery helps people with locally advanced, CLDN18.2-positive stomach cancer shrink tumors and have better outcomes.

  Recruiting at 2 sites Phase 1/2 Asan Medical Center · Seoul and 1 other locations · NCT06732856

• Combining radiotherapy and immunotherapy for limited metastatic gastric cancer

  This study is testing a new treatment that combines radiation, chemotherapy, and immunotherapy to see if it can help people with limited metastatic gastric cancer live longer and improve their health.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06121700

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.